There are no data concerning the significance of allergen specific nasal challenge to latex (ASNCL) in the pediatric population and the effect of mom etasone furoate nasal spray [(MFNS), topic corticosteroid exerting a potent anti-inflammatory activity] in children with latex allergic rhinitis. The aims of this study are: to investigate the clinical and immune pathological effects of ASNCL in children with latex allergy; to study the effects of MFNS pre-medication on the clinical and immune pathological effects of ASNCL in children with latex allergy. Thirteen children [6 male and 7 female, mean (SD) age 9.6 (2.9) years] with latex allergy and seven children [3 male and 4 female, mean (SD) age 9.9 (3.8) years] without latex allergy underwent ASNCL. Nasal symptoms were recorded, nasal lavage fluid was collected to measure tryptase, eosinophil cationic protein (ECP), interleukin-5, interferon-y levels, and spirometric test was performed for each patient without or with pre-medication with MFNS. ASNCL induced a clinical allergic response and increased tryptase levels only in children with latex allergy. No serious adverse events occurred after ASNCL. MFNS pre-medication reduced both tryptase and ECP levels only in children with latex allergy. ASNCL is a simple, reliable and useful tool to make or confirm the diagnosis of nasal symptoms due to latex; it allows us to study both clinical symptoms and local immunological changes. MFNS pre-medication before an ASNCL may prevent some immunological responses induced by ASNCL without clinical allergic modifications.
skin prick test (SPT) to latex, and determination of specific serum immunoglobulin E (lgE) to latex, may be not sufficient to achieve a correct diagnosis of allergic rhinitis due to latex allergy (8) . Allergen specific nasal challenge is a diagnostic procedure that can be performed to reach a diagnosis of allergic rhinitis through the identification of the suspected allergen. As previously shown, nasal challenge could be useful not only as a research tool but also for diagnosing occupational rhinitis in latex-sensitized workers (9) .
Therefore, the first aim of this study is to investigate the clinical and immune pathological effects induced by allergen specific nasal challenge to latex (ASNCL) in children with suspected latex allergy: there are no studies regarding this issue in pediatric age.
Except for allergen avoidance, intranasal corticosteroids are often an effective choice to treat allergic rhinitis because of their strong anti-inflammatory activity (10) . In this regard, mometasone furoate nasal spray (MFNS), (Nasonex, Schering Plough SpA, Segrate, Milan, Italy) has been demonstrated to prevent allergic nasal symptoms due to inhalant allergens (11) . In addition, MFNS premedication affects the late phase events following allergen specific nasal challenge (12) . Therefore, this drug might prevent nasal symptoms in patients with nasal manifestations due to latex exposure.
The second aim of this study is to investigate the clinical and immunological effects of MFNS premedication on ASNCL. Table I represents the study design. Thirteen children [6 male and 7 female, mean (SD) age 9.6 (2.9) years] (group A) with clinical manifestations due to suspected latex allergy (rhinitis in all 13, urticaria in 6 patients, asthma in 6 patients, and conjunctivitis in 2 patients) were enrolled in the Pediatric Allergy and Pulmonology Center of the Anna Meyer Children's Hospital of Florence (Italy).
MATERIALS AND METHODS

Patients
Symptoms occurred after exposure to latex products (surgical procedures performed by a dentist in 12 patients, surgical gloves in 9 patients, rubber balloons in 8 patients, household cleaning gloves in 5 patients, and swimming caps in 3 patients).
Seven children [3 male and 4 female, mean (SD) age 9.9 (3.8) years], without clinical manifestations due to latex products were also enrolled as control group (group B). SPT to latex was performed according to the recommendations of the European Academy of Allergology and Clinical Immunology (13) using a commercial extract supplied by the "Laboratorio Lofarma" (Milan, Italy) (12) (13) , and the presence of specific serum IgE to latex (UniCAP Pharmacia, Uppsala, Sweden) was detected according to the manufacture's instructions. Positive and negative controls (histamine and saline solution respectively) were additionally performed.
In each of subjects SPTs to common aeroallergens (16) were performed.
SPTs were considered positive if the wheal's diameter was 2: 3 mm (13). Specific serum IgE to latex were considered positive over 0.35 kU/llevels.
Topical or systemic drugs were avoided during the study. Informed consent was obtained from the parents of all children enrolled. The study was performed according to the Conference of Helsinki.
Nasal lavage fluid
Nasal lavage fluid (NLF) with saline solution was collected before and after the nasal challenge according to the procedure described in a previous study (17) . Saline pre-wash was conducted in a single blind manner. Briefly, NLF was performed for approximately I minute, 6 ml of normal saline were sprayed into the nose, the fluid collected was filtered (22 micron Millipor filter), centrifuged for 10 minutes and then frozen at -20 DC (17).
Allergen specific nasal challenge to latex
Group A and B patients underwent the allergen specific nasal challenge to latex (ASNCL) as previously described (17) .
A washout period (drug free) of 4 weeks without nasal symptoms was established before the ASNCL.
In order to determine the latex concentration which could be used to start the ASNCL in group A, an SPT was performed using a latex concentration 500 times lower than that of the commercial latex extract used to confirm the diagnosis of latex allergy. If it was negative (wheal < 3 mm), the SPT was repeated using concentrations 100, 50 and 10 times lower than that of the commercial latex extract.
The undiluted commercial latex extract had a protein concentration of 46 ug/ml (using a previously described method) (14) (15) (16) (17) . Immediately before the ASNCL, a nasal non-specific provocationtest (100 ul in each nostril)with the vehicle used to prepare commercial latex SPT (13) (14) (15) was carried out on each child as previously described (17) .
The ASNCL was performed by spraying in each nostril 100 ul of the same commercial latex extract used for the SPT at the lowest concentration that had developed a wheal 2: 3 mm. This method was used to avoid possible adverse and dangerous reactions to high latex concentrations. The device used for spraying the latex extract was similar to that used to perform the NLF as already described (17) . The ASNCL was continued using the next higher latex concentration until the symptom score turned positive (i.e. if the ASNCL was negative at the 1:500 concentration, another ASNCL was performed at the 1:100 concentration after 30 minutes, and so on until the concentration that provoked a symptom score 2: 5 was reached).
Immunological evaluation
Tryptase (Pharmacia, Uppsala, Sweden), eosinophil cationic protein (ECP) (Pharmacia, Uppsala, Sweden), interleukin-5 (IL-5) (R & D System, Minneapolis, USA), and interferon-y (INF-y) (R & D System, Minneapolis, USA) levels were detected according to the manufacturer's instructions. The NFL was collected at the times specified in Table I .
Symptoms
Nasal symptoms were assessed after the ASNCL according to a known symptom score system (positive if 2: 5). The number of sneezes and the degree of rhinorrhea, mucosal edema, and itching were recorded. The total symptom scores ranged from 0 to 14 and represented the sum of the scores established for sneezing (4 or more sneezes: 1 point), rhinorrea (mild anterior and posterior: 1 point; abundant anterior and posterior: 3 points), mucosal edema (difficult breathing: 1 point; one nostril block: 2 point; nasal block: 3 points), and itching (itching of the nose: 1 point; itching of the throat: 1 point; itching of the eyes: 1 point). The clinical challenge was considered positive if the total score corresponded to 5 or more points (9) (10) (11) (12) (13) (14) (15) (16) (17) .
Spirometric indices
Spirometric indices were evaluated before and after the ASNCL (Table I ) ) . FEV/FVC ratio lower than 88% predicted was used to define a spirometric bronchial obstruction. A decrease in FEV, higher than 12% was considered to be a significant change after the ASNCL(l8).
IMtIicQtionwith MFNS NLF, ASNCL, and spirometry were repeated 35 days l3tet:, feIowing a 5~pre-medication with MFNS (100 ug daily in each nostril: total dose 200 ug daily) and about 12 hours after the last administration of this drug (Table I) .
Statistical analysis
All data were analyzed with a commercial statistical package (SPSS for Windows). The Student t test for independent or paired samples as appropriate was used to compare means. P values < 0.05 were considered significant.
RESULTS
Specific IgE in patients
In group A the wheal's mean (SD) value of SPT to latex and the UniCAP mean (SD) value of specific IgE to latex was respectively 6.3 mm (3.4) and 29.2 kU/1 (27.3).
Five out of thirteen (38.5%) children were IgE sensitized to one or more of the common aeroallergens.
In group B SPT to latex was negative and specific serum IgE to latex were absent. Two children (28.5%) were IgE sensitized to one or more of the common aeroallergens.
Allergen specific nasal challenge to latex
There was no appearance of symptoms after a nasal non-specific provocation test in all children.
In group A, ASNCL induced nasal and other symptoms (symptoms score > 5) both without (13/ 13, 100%) or with (12/13, 92.3%) an MFNS premedication (Tables II and III ). In the entire group B, ASNCL did not induce nasal or other symptoms. ASNCL was well tolerated in all children and no adverse events were present.
Immunological evaluation
In Fig. 1 and Table IV However, in group A we found: 1) significantly higher levels of tryptase 30 minutes (Fig. I ) after a positrve ASNCL in comparison to basal values; after MFNS treatment this observation was undetectable; 2) significantly ECP basal lower levels before MFNS treatment if compared with ECP basal levels after MFNS treatment (Fig. I) .
In group B no significant modifications of these (tryptase, ECP) and other (IL-5, INF-y) parameters were observed after ASNCL.
Symptoms and Spirometric indices
There were no significant changes in the symptom score (Tables II and III) and spirometric indices  (FEVI' FVC and FEV 25 • 75 values) (data not shown) either before or after a positive ASNCL without and with MFNS treatment (group A). In group B there were no symptoms or changes in spirometric indices after ASNCL.
DISCUSSION
Specific nasal challenge test is used to confirm the causal relationship between allergen exposure and symptom appearance (19) . Various allergens are used for specific nasal challenge (e.g. birch, grass, rye, mugwort and plantain) (20) . However, specific nasal challenge with latex has been used only in adult patients (9-21).
Kurtz and co-workers have developed a hooded exposure chamber system to allow evaluation of rhino-conjunctivitis and asthma, especially in health care workers after latex exposure (20) . This is a method for masked semi-quantitative latex aeroallergen challenges that mimic occupational latex exposure to powdered latex gloves. The patients presented only respiratory symptoms after the latex provocation test and did not experience 3) NLF (tryptase, ECP, INF-y and IL-5); 4) ASNCL.
TableI. Study design (without or with a pre-medication with MFNS).
Patients group A (patients with latex allergy)
• 4
Time 0 • systemic or late-phase reactions. Palczynski and co-workers evaluated the usefulness of a nasal challenge test in the diagnosis of allergic rhinitis in subjects occupationally exposed to natural rubber latex products (9) . The nasal provocation test with natural rubber latex provoked nasal symptoms in subjects who presented respiratory symptoms related to natural rubber latex. To our knowledge, there are no relative studies in pediatric age.
Our study mostly provides evidence that ASNCL is a safe and reliable test to make diagnosis of latex allergy in children with suspected nasal symptoms due to latex exposure. Neither bronchial nor systemic reactions were observed after the ASNCL.
We show that all children sensitized to latex and with suspected latex allergy had clinical responses to ASNCL, whereas children without latex allergy did not respond to the challenge. Therefore ASNCL may be performed in children with suspected latex allergy as an additional and confirming diagnostic test.
In the nasal lavage Palczynski and co-workers (9) noted a significant increase of ECP levels 24 hours after a challenge with natural rubber latex while we did not find any statistically significant change in ECP concentration. We detected significantly higher levels of tryptase 30 minutes after a positive ASNCL in comparison to basal values. Bellussi and co-workers showed a significant increase oftryptase levels after a specific nasal provocation test in mite allergic patients without a significant ECP increase (22) .
Other authors studied the changes of mediators (cytokines: IL-3, IL-4, IL-5, IL-8, IL-IO, IL-13) and cells (eosinophils and macrophages) in nasal lavage fluid after a specific nasal provocation test using grass pollen (23) (24) .
Topical corticosteroids (e.g. mometasone furoate, I  3  3  0  1  4  2  2  6  3  6  4  3  5  5  7  6  4  6  7  2  6  8  2  4  6  9  2  6  10  2  7  11  0  1  1  6  12  4  7  13  0  2  4  7 budesonide, fluticasone propionate) are effective in the treatment of allergic rhinitis (25) , acting on both the early and late phases of allergic inflammation (26) , therefore, a pre-treatment with these drugs seems to be recommendable. In our study a 5 day pre-medication at a dosage of 100 ug daily in each nostril did not prevent nasal symptoms resulting from ASNCL. But there are other studies about the efficacy of a pre-treatment with nasal steroid on the avoidance of rhinitis appearance due to other allergens. The mean nasal symptom scores and sneezing frequency were consistently lower with mometasone furoate pretreatment compared with placebo after a nasal challenge with ragweed antigen in patients with allergic rhinitis to ragweed (26) .
A prevention of nasal symptoms has been described in patients with seasonal allergic rhinitis pre-treated with fluticasone propionate (l00 ug bd into each nostril for 7 days), and receiving a nasal allergen challenge with timothy grass pollen after the treatment, far from the hay fever season (27) .
It is possible that higher dosages or a longer period of administration of mometasone furoate might determine a clinical protective effect in children with nasal symptoms due to latex products. This protection has been demonstrated with a longer period of administration of mometasone furoate in presence of nasal symptoms due to seasonal inhalant allergens (II). In our study a pre-treatment longer than 5 days was not possible because of a poor compliance.
Moreover, our study demonstrates no correlation between the presence of immunological changes (27) . In patients with grass pollen seasonal-allergic rhinitis out of season receiving specific nasal challenge, fluticasone propionate (100 ug bd into each nostril for 7 days in 13 patients) induced a significant reduction of some cytokines (IL-4, IL-5, IL-6, IL-13) and chemokines (eotaxin, RANTES, MCP-1, MIP-1a, IL-8 and IP-10) in nasal secretions in the late phase if compared with the levels before the start of the nasal therapy while INF-y levels were not modified (28) . The absence of modifications of IL-5 levels in our study compared to the Erin and co-workers' study (28) may be due to: 1) different efficacy between fluticasone propionate and mometasone furoate, 2) different response to one allergen (e.g. timothy grass pollen) versus another allergen (e.g. latex).
In conclusion, ASNCL, in patients with suspected nasal symptoms to latex, is a simple, reliable and useful tool to confirm a diagnosis of allergic rhinitis to latex. In patients with nasal symptoms to latex exposure and with specific IgE to latex, ASNCL is a useful tool to study immunological modifications in NLF (e.g. tryptase, ECP, INF-y, IL-5 and e.g. other mediators not evaluated in this report). Finally, MFNS pre-medication before an ASNCL may prevent some immunological responses (e.g. tryptase and ECP level modifications) induced by ASNCL.
